The Changing Landscape of Renal Cell and Bladder Cancers: Role of Immune Checkpoint Inhibitors

Released On
July 5, 2018

Expires On
July 5, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Nephrology, Oncology, Urology

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Academy for Continued Healthcare Learning and The University of Texas MD Anderson Cancer Center.

 

Supported by an educational grant from Bristol-Myers Squibb.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for medical oncologists and advanced practitioners (NP/PA/PharmD) interested in the treatment of genitourinary cancers such as renal cell carcinoma and bladder cancer.

Statement of Need/Program Overview

Immune checkpoint inhibitors offer hope for patients with either renal cell carcinoma or bladder cancer who cannot receive platinum-based chemotherapy, or who may not have responded or have stopped responding to traditional chemotherapy regimens. However, identifying the patients who stand to benefit the most from systemic immunotherapy and managing potential, associated adverse events are clinical challenges not well-addressed by existing guidelines. This webcast is led by expert faculty who review how to optimally employ these novel therapies in practice in order to improve patient health and outcomes.

Learning Objectives

Goals:

Increased comprehension of how immunotherapeutic agents work to decrease tumor burden and improve patient outcomes in genitourinary cancers. (Knowledge, Competence)

  • Recognition of patients who may benefit from novel treatment approaches. (Knowledge, Competence, Performance)
  • An enhanced understanding of how the immunotherapy landscape for renal cell carcinoma and bladder cancer is changing. (Knowledge, Competence)
  • Increased understanding of the impact of PD-L1 on response and outcomes, and selection of appropriate immunotherapies based on patient factors. (Knowledge, Competence)
  • Early recognition of irAEs and the ability to mitigate them before they become severe. (Knowledge, Competence, Performance)

Upon completion of this activity, participants should be able to:

  • Outline current unmet clinical needs in the treatment of renal cell carcinoma and bladder cancer
  • Examine the evidence for targeting the PD-1/PD-L1 pathway and CTLA-4 in immuno-oncology, including the use of checkpoint inhibitors
  • Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies impact renal cell carcinoma and bladder cancer
  • Discuss clinical factors and biomarkers that may be predictive of prognosis and response to immunotherapies in renal cell carcinoma and bladder cancer
  • Identify immune-related adverse events and develop a management plan to help mitigate them

Faculty

Nizar Tannir, MD, FACP

Professor and Deputy Chairman
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer CenterHouston, TX

(Planning Committee) Matthew Campbell, MD, MS

Assistant Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer CenterHouston, TX

Physician Accreditation Statement

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Texas MD Anderson designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the Department of CME/Conference Management at 713/792-5357.

The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

ACHL and MD Anderson require that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Matthew T. Campbell, MD, MS (Co-Chair/Planning Committee)

  • Consulting Agreements: Astra Zeneca, Eisai

Nizar Tannir, MD, FACP (Co-Chair/Planning Committee)

  • Sources of Funding for Research: BMS, Epizyme, Exelixis, Miranti, Novartis
  • Consulting Agreements: Argos, BMS, Eisai, Exelixis, Nektar, Novartis, Oncorena, Pfizer
  • Advisory Committee Member: Eisai, Exelixis, Nektar, Novartis, Oncorena

ACHL, The University of Texas MD Anderson Cancer Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Tarra Barot, Oliver Bogler, PhD, Katlyn Cooper, Larry Driver, MD, Khalid Elsayes, MD, Elizabeth Fortino, Tamara C. Greiner, MA, CHCP, LaTarsha Johnson, Amanda Kaczerski, Brittany Puster, Karin Woodman, MD.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and MD Anderson require the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Phase 3 therapies/combinations of therapies in clinical trials for RCC and bladder cancer.

Method of Participation

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online activity and complete the post-test and evaluation. To receive credit, 60% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation. Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.

For questions, contact Liz Fortino at efortino@achlcme.org.

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and MD Anderson require the speaker to disclose that a product is not labeled for the use under discussion.